TL;DR
- The FDA enforcement ladder has six rungs, and a Warning Letter — the one most people fear — is only rung two (FDA: Warning Letters).
- Rungs one and two are advisory: an Untitled Letter carries no enforcement warning, while a Warning Letter explicitly does (FDA: Untitled Letters).
- Rungs four through six are judicial: seizure, injunction, and consent decree all involve a federal court, not just FDA correspondence (FDA Regulatory Procedures Manual, Ch. 6).
- A consent decree is the ceiling — the company pays for its own FDA oversight at 267% of standard hourly rates until an independent expert certifies compliance (FDA RPM, Ch. 6, §§6-1-9, 6-2-13 to 6-2-15).
- Escalation past a Warning Letter is the exception, not the rule — but Pharmasol went from a 2019 Warning Letter to a 2023 consent decree after repeat CGMP failures (FDA press announcement).
What Are the Six Rungs of FDA's Enforcement Escalation Ladder?
If you think a Warning Letter is the worst thing FDA can do to your company, you're wrong, and that misunderstanding gets compliance teams in trouble. A Warning Letter is rung two of six. There are four more, harder rungs above it, and none of them come with a comment period.
The confusion is understandable. Warning Letters are public, searchable, and carry real reputational cost. But they're still advisory correspondence. Everything above rung two involves a federal court, a judge, and, eventually, a company's own money paying for FDA to watch it.
Rungs 1-2: The Advisory Actions
1. Untitled Letter. This is the mildest tool in FDA's kit. By definition, an Untitled Letter "does not include a statement that warns the individual or firm that failure to promptly correct the violation may result in enforcement action." FDA reserves it for violations that don't rise to the level of "regulatory significance" required for a Warning Letter (FDA: Untitled Letters). No warning language, no escalation threat baked into the document itself.
2. Warning Letter. One step up, and the step matters. A Warning Letter is issued "to achieve voluntary compliance and to establish prior notice," specifically for "violations of regulatory significance that may lead to enforcement action if not promptly and adequately corrected" (FDA: Warning Letters). That "may lead to enforcement action" clause is the entire difference between rung one and rung two. It's still a letter. It is not yet a lawsuit. For a full breakdown of how these two compare, see What's the difference between an FDA Untitled Letter and a Warning Letter?
Rung 3: The Border Action
3. Import Alert / Detention Without Physical Examination (DWPE). This is where things stop being purely advisory. Once a firm or product lands on an Import Alert, FDA can detain future shipments at the border without physically examining each one, operating under the "appearance" standard of FD&C Act Section 801 (21 U.S.C. § 381) (FDA: Import Alerts). It's not judicial, but it's not just a letter either — it's an operational lockout that can choke off a supply chain overnight. For the mechanics of how DWPE actually works, see What is an FDA Import Alert, and what does DWPE mean?
Rungs 4-6: The Judicial Actions
This is where FDA stops writing and starts filing.
4. Seizure. A seizure is a judicial action filed under 21 U.S.C. § 334, and it's a genuinely strange legal animal: the government sues the product, not the company. FDA's own manual describes it plainly — "The United States of America, as plaintiff, proceeds [in rem against the article itself]," and "if there is no proper claimant, the United States is entitled to condemnation and forfeiture by default" (FDA Regulatory Procedures Manual, Ch. 6, §6-1). The case name is literally U.S. v. [product]. Your inventory goes into court custody. You don't have to be personally named to lose it.
5. Injunction. An injunction is "a civil judicial process initiated to stop or prevent violation of the law, such as to halt the flow of violative products in interstate commerce, and to correct the conditions that caused the violation to occur," brought under 21 U.S.C. § 332 and Rule 65 of the Federal Rules of Civil Procedure (FDA RPM, Ch. 6, §6-2-2). It can arrive as a 10-day emergency temporary restraining order, a preliminary injunction, or a permanent one. FDA's manual is direct about who's a target: a firm with "a history of violations" that "has promised correction in the past, but has not made the corrections" is exactly the profile injunctions are built for. Once granted, FDA doesn't walk away — the agency "has a continuing duty to monitor the injunction and to advise the court if the defendants fail to obey the terms" (FDA RPM, Ch. 6, §6-2-3).
6. Consent Decree of Permanent Injunction. The top rung, and the most expensive one. A consent decree is a permanent injunction the defendant agreed to rather than fought at trial. FDA's Office of Chief Counsel (OCC) "will prepare a consent decree which may include provisions for injunctive relief" (FDA RPM, Ch. 6, §6-1-9). The company typically has to hire, at its own cost, an independent expert consultant who certifies compliance in writing before FDA will even schedule a reinspection. Every FDA inspection conducted under the decree gets billed back to the company, at 267% of the GS-11/4 hourly rate for investigation time and 267% of the GS-12/4 rate for analytical time (FDA RPM, Ch. 6, §§6-2-13 to 6-2-15). Operations stay shut until FDA agrees, in writing, that conditions have been met. Pharmasol Corporation lived this path: a 2019 Warning Letter, unresolved CGMP failures, a 2022 inspection where most observations repeated prior ones, and a consent decree entered December 14, 2023 (FDA press announcement). The full timeline is broken down in What Is an FDA Consent Decree? A Timeline From Warning Letter to Court Order.
The Ladder, Side by Side
| Rung | Action | Legal basis | Who initiates | What happens |
|---|---|---|---|---|
| 1 | Untitled Letter | Agency correspondence, no statutory enforcement citation | FDA compliance office | Notice of violation; no "may result in enforcement action" language |
| 2 | Warning Letter | Agency correspondence, prior-notice standard | FDA compliance office | Formal notice that uncorrected violations may lead to enforcement action |
| 3 | Import Alert / DWPE | FD&C Act § 801 (21 U.S.C. § 381) | FDA field/import operations | Future shipments detained at border without physical exam |
| 4 | Seizure | 21 U.S.C. § 334 | U.S. Attorney, on FDA's behalf, in rem against the product | Product physically removed from commerce into court custody |
| 5 | Injunction | 21 U.S.C. § 332; Rule 65 FRCP | U.S. Attorney/DOJ, on FDA's behalf, against the firm or individual | Court orders company to stop/start specific conduct; FDA monitors compliance |
| 6 | Consent Decree of Permanent Injunction | 21 U.S.C. § 332; negotiated settlement | Company and DOJ/FDA jointly | Permanent court order; company funds independent expert and all future FDA oversight at 267% GS-11/12 rates |
FAQ
Is a Warning Letter the most severe action FDA can take?
No. It's rung two of six. Everything from Import Alerts through consent decrees sits above it, and rungs four through six involve a federal court rather than agency correspondence alone (FDA: Warning Letters; FDA RPM, Ch. 6).
How often does a Warning Letter turn into a seizure or injunction?
There's no published FDA statistic quantifying this, and escalation past a Warning Letter is the exception rather than the rule. What pushes a case up the ladder, per FDA's own manual, is a documented history of violations combined with promised corrections that never materialized (FDA RPM, Ch. 6, §6-2-2).
What makes a consent decree different from a regular injunction?
Both are permanent injunctions under 21 U.S.C. § 332. The difference is that a consent decree is negotiated and agreed to by the defendant rather than imposed after a contested trial, and it typically layers on additional obligations, an independent expert certification and reimbursement of FDA's oversight costs at 267% of standard hourly rates, that a bare injunction doesn't automatically include (FDA RPM, Ch. 6, §§6-1-9, 6-2-13 to 6-2-15).
Related reading
- What's the difference between an FDA Untitled Letter and a Warning Letter?
- What is an FDA Import Alert, and what does DWPE mean?
- What Is an FDA Consent Decree? A Timeline From Warning Letter to Court Order
Argus $99 vs FDAzilla $5k/yr — see why →
Sources: FDA: Issuance of Untitled Letters, FDA: Warning Letters, FDA: Import Alerts, FDA Regulatory Procedures Manual, Chapter 6: Judicial Actions, FDA press announcement: Federal Court Enters Consent Decree Against Pharmasol. Byline: The Argus Regulatory Analysis Team. Published 2026-07-14.